The neuropathological confirmation of amyloid β (Aβ) plaques and tau neurofibrillary tangles (NFT) remains the gold standard for a definitive diagnosis of Alzheimer's disease (AD). This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.